Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was ap...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/4/634 |
| _version_ | 1797606242817933312 |
|---|---|
| author | Henning Olbrich Christian D. Sadik Ralf J. Ludwig Diamant Thaçi Katharina Boch |
| author_facet | Henning Olbrich Christian D. Sadik Ralf J. Ludwig Diamant Thaçi Katharina Boch |
| author_sort | Henning Olbrich |
| collection | DOAJ |
| description | Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases. |
| first_indexed | 2024-03-11T05:12:25Z |
| format | Article |
| id | doaj.art-cf0883dce6ae4fe29df846ba5bf0813f |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T05:12:25Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-cf0883dce6ae4fe29df846ba5bf0813f2023-11-17T18:29:13ZengMDPI AGBiomolecules2218-273X2023-03-0113463410.3390/biom13040634Dupilumab in Inflammatory Skin Diseases: A Systematic ReviewHenning Olbrich0Christian D. Sadik1Ralf J. Ludwig2Diamant Thaçi3Katharina Boch4Department of Dermatology, University of Lübeck, 23566 Lübeck, GermanyDepartment of Dermatology, University of Lübeck, 23566 Lübeck, GermanyDepartment of Dermatology, University of Lübeck, 23566 Lübeck, GermanyDepartment of Dermatology, University of Lübeck, 23566 Lübeck, GermanyDepartment of Dermatology, University of Lübeck, 23566 Lübeck, GermanyDupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was approved by the U.S. Food and Drug Administration for prurigo nodularis (PN). Given its relatively good safety profile, effective off-label use of dupilumab has been reported for a multitude of dermatologic diseases and several clinical trials for dermatologic skin conditions are currently ongoing. We conducted a systematic review of applications of dupilumab in dermatology other than AD and PN by searching the databases PubMed/Medline, Scopus, Web of Science and Cochrane Library as well as the clinical trial registry ClinicalTrials.gov. We found several reports for effective treatment of bullous autoimmune diseases, eczema, prurigo, alopecia areata, chronic spontaneous urticaria, Netherton syndrome and a variety of other chronic inflammatory skin diseases.https://www.mdpi.com/2218-273X/13/4/634dupilumabatopic dermatitisreviewprurigo nodularispruritusalopecia areata |
| spellingShingle | Henning Olbrich Christian D. Sadik Ralf J. Ludwig Diamant Thaçi Katharina Boch Dupilumab in Inflammatory Skin Diseases: A Systematic Review Biomolecules dupilumab atopic dermatitis review prurigo nodularis pruritus alopecia areata |
| title | Dupilumab in Inflammatory Skin Diseases: A Systematic Review |
| title_full | Dupilumab in Inflammatory Skin Diseases: A Systematic Review |
| title_fullStr | Dupilumab in Inflammatory Skin Diseases: A Systematic Review |
| title_full_unstemmed | Dupilumab in Inflammatory Skin Diseases: A Systematic Review |
| title_short | Dupilumab in Inflammatory Skin Diseases: A Systematic Review |
| title_sort | dupilumab in inflammatory skin diseases a systematic review |
| topic | dupilumab atopic dermatitis review prurigo nodularis pruritus alopecia areata |
| url | https://www.mdpi.com/2218-273X/13/4/634 |
| work_keys_str_mv | AT henningolbrich dupilumabininflammatoryskindiseasesasystematicreview AT christiandsadik dupilumabininflammatoryskindiseasesasystematicreview AT ralfjludwig dupilumabininflammatoryskindiseasesasystematicreview AT diamantthaci dupilumabininflammatoryskindiseasesasystematicreview AT katharinaboch dupilumabininflammatoryskindiseasesasystematicreview |